<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7941714</article-id><article-id pub-id-type="publisher-id">7995</article-id><article-id pub-id-type="doi">10.1186/s12885-021-07995-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jingyi</given-names></name><address><email>jychen95@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Yuxuan</given-names></name><address><email>yuxuan_song2013@163.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Mei</given-names></name><address><email>meimei7810@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yu</given-names></name><address><email>zhangyu_zxy@bjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Tingru</given-names></name><address><email>tingru_lin1997@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Jie</given-names></name><address><email>sjsslc@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Di</given-names></name><address><email>ellen_wd@sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yulan</given-names></name><address><email>liuyulan@pkuph.edu.cn</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Guo</surname><given-names>Jingzhu</given-names></name><address><email>gjzhxx@sina.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7573-4979</contrib-id><name><surname>Yu</surname><given-names>Weidong</given-names></name><address><email>weidongyu@bjmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Department of Central Laboratory &#x00026; Institute of Clinical Molecular Biology, </institution><institution>Peking University People&#x02019;s Hospital, </institution></institution-wrap>Beijing, 100044 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Department of Gastroenterology, </institution><institution>Peking University People&#x02019;s Hospital, </institution></institution-wrap>Beijing, 100044 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412645.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 1757 9434</institution-id><institution>Department of Urology, </institution><institution>Tianjin Medical University General Hospital, </institution></institution-wrap>Tianjin, 300052 China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Department of Paediatrics, </institution><institution>Peking University People&#x02019;s Hospital, </institution></institution-wrap>Beijing, 100044 China </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>21</volume><elocation-id>255</elocation-id><history><date date-type="received"><day>3</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>2</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Competing endogenous RNA (ceRNA) represents a class of RNAs (e.g., long noncoding RNAs [lncRNAs]) with microRNA (miRNA) binding sites, which can competitively bind miRNA and inhibit its regulation of target genes. Increasing evidence has underscored the involvement of dysregulated ceRNA networks in the occurrence and progression of colorectal cancer (CRC). The purpose of this study was to construct a ceRNA network related to the prognosis of CRC and further explore the potential mechanisms that affect this prognosis.</p></sec><sec><title>Methods</title><p id="Par2">RNA-Seq and miRNA-Seq data from The Cancer Genome Atlas (TCGA) were used to identify differentially expressed lncRNAs (DElncRNAs), microRNAs (DEmiRNAs), and mRNAs (DEmRNAs), and a prognosis-related ceRNA network was constructed based on DElncRNA survival analysis. Subsequently, pathway enrichment, Pearson correlation, and Gene Set Enrichment Analysis (GSEA) were performed to determine the function of the genes in the ceRNA network. Gene Expression Profiling Interactive Analysis (GEPIA) and immunohistochemistry (IHC) were also used to validate differential gene expression. Finally, the correlation between lncRNA and immune cell infiltration in the tumor microenvironment was evaluated based on the CIBERSORT algorithm.</p></sec><sec><title>Results</title><p id="Par3">A prognostic ceRNA network was constructed with eleven key survival-related DElncRNAs (MIR4435-2HG, NKILA, AFAP1-AS1, ELFN1-AS1, AC005520.2, AC245884.8, AL354836.1, AL355987.4, AL591845.1, LINC02038, and AC104823.1), 54 DEmiRNAs, and 308 DEmRNAs. The MIR4435-2HG- and ELFN1-AS1-associated ceRNA subnetworks affected and regulated the expression of the COL5A2, LOX, OSBPL3, PLAU, VCAN, SRM, and E2F1 target genes and were found to be related to prognosis and tumor-infiltrating immune cell types.</p></sec><sec><title>Conclusions</title><p id="Par4">MIR4435-2HG and ELFN1-AS1 are associated with prognosis and tumor-infiltrating immune cell types and could represent potential prognostic biomarkers or therapeutic targets in colorectal carcinoma.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12885-021-07995-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>ceRNA network</kwd><kwd>lncRNA</kwd><kwd>Immune infiltration</kwd><kwd>Prognosis</kwd><kwd>CRC</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>30872923</award-id><award-id>81672853</award-id><principal-award-recipient><name><surname>Yu</surname><given-names>Weidong</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par28">Colorectal cancer (CRC), the third most common cancer and the second leading cause of cancer mortality worldwide, is caused by the accumulation of long-term genetic mutations and epigenetic alterations [<xref ref-type="bibr" rid="CR1">1</xref>]. Although recent interventional and therapeutic advances have greatly improved the overall survival (OS) of CRC, patients with advanced CRC still show poor prognosis due to the high frequency of recurrence and metastasis [<xref ref-type="bibr" rid="CR2">2</xref>]. Investigation of the molecular mechanisms underlying CRC, from initiation to metastasis, is urgently needed to improve its early diagnosis, treatment, and prognosis. Long noncoding RNAs (lncRNAs) are noncoding transcripts that range from 200 to 100,000 nucleotides in length and lack protein-coding capacity. They function as signals, decoys, guides, and scaffolds in gene regulatory networks [<xref ref-type="bibr" rid="CR3">3</xref>]. The regulatory mechanism of lncRNA depends on its subcellular localization. Cytoplasmic lncRNAs primarily participate in post-transcriptional and translational regulation by acting as microRNA (miRNA) sponges and modulating mRNA stability. An increasing number of lncRNAs have been found to participate in CRC initiation and progression by functioning as competing endogenous RNAs (ceRNAs) [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Specifically, lncRNAs derepress target gene expression by competitively binding to shared sequences of miRNAs [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Recent studies showed that ceRNA crosstalk was involved in various biological processes, including CRC cell proliferation, invasion, epithelial-to-mesenchymal transition (EMT), metastasis, and immune infiltration [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par29">In the present study, we acquired the expression profiles and clinical information for colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) from The Cancer Genome Atlas (TCGA). Differentially expressed mRNAs (DEmRNAs), lncRNAs (DElncRNAs), and miRNAs (DEmiRNAs) were then identified by comparing tumor samples and normal samples. We performed survival analysis and predicted RNA interaction pairs to construct a prognosis-related ceRNA network. The protein&#x02013;protein interaction (PPI) network was embodied in Cytoscape to identify module clusters and hub genes. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed to explore the biological functions of the mRNAs in the ceRNA and module network. In addition, we analyzed the correlations between key lncRNAs and the clinical features of CRC patients. Co-expression analysis between lncRNAs and target genes was performed to verify the ceRNA hypothesis. Eventually, we established ceRNA regulatory subnetworks based on the above results. GEPIA and immunohistochemistry were used to validate the differential expression of genes, whereas GSEA was used to predict the underlying functions of the genes in the subnetwork. The CIBERSORT algorithm was used to estimate the proportion of immune cells for further correlation analysis (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).
<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart for the identification and analysis of prognostic lncRNAs in the ceRNA network</p></caption><graphic xlink:href="12885_2021_7995_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data downloading and pre-processing</title><p id="Par30">The mRNA, lncRNA, and miRNA expression profiles of the CRC patients were downloaded from TCGA database (<ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/">https://cancergenome.nih.gov/</ext-link>). We collected RNA-Seq data for 612 samples (568 CRC and 44 normal samples) in HTSeq-Counts files and miRNA-Seq data for 548 samples (539 CRC and nine normal samples). The sequence data were derived from Illumina HiSeq RNASeq and miRNASeq platforms, which were publicly available. GENCODE (<ext-link ext-link-type="uri" xlink:href="https://www.gencodegenes.org/">https://www.gencodegenes.org/</ext-link>) was used to convert the RNA-Seq data into lncRNAs (sense_overlapping, lincRNA, 3prime_overlapping_ncRNA, processed_transcript, antisense, and sense_intronic) and mRNAs (protein-coding).</p></sec><sec id="Sec4"><title>Differential expression analysis of RNAs</title><p id="Par31">To screen differentially expressed RNAs (DERNAs) between tumor samples and normal samples, we used the &#x0201c;edgeR&#x0201d; package in R software to standardize and analyze the downloaded data. DEmRNAs, DElncRNAs, and DEmiRNAs were identified with the criteria of |log2 fold change (FC)|&#x02009;&#x0003e;&#x02009;1.0 and adjusted <italic>P</italic> value &#x0003c;&#x02009;0.05. Heatmap clustering and volcano plot were generated using R package &#x0201c;edgeR&#x0201d; to reveal the differential expressions of the DEmRNAs, DElncRNAs, and DEmiRNAs.</p></sec><sec id="Sec5"><title>Prediction of RNA interaction pairs</title><p id="Par32">The online tool DIANA-LncBase version 3 (<ext-link ext-link-type="uri" xlink:href="http://www.microrna.gr/LncBase">http://www.microrna.gr/LncBase</ext-link>) [<xref ref-type="bibr" rid="CR14">14</xref>] was used to predict the potential miRNAs targeted by DElncRNAs and determine lncRNA&#x02013;miRNA interaction pairs. MiRDB (<ext-link ext-link-type="uri" xlink:href="http://www.mirdb.org/">http://www.mirdb.org/</ext-link>) [<xref ref-type="bibr" rid="CR15">15</xref>], miRTarBase (<ext-link ext-link-type="uri" xlink:href="http://mirtarbase.mbc.nctu.edu.tw/">http://mirtarbase.mbc.nctu.edu.tw/</ext-link>) [<xref ref-type="bibr" rid="CR16">16</xref>], and TargetScan (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/">http://www.targetscan.org/</ext-link>) [<xref ref-type="bibr" rid="CR17">17</xref>] databases were used to predict the target genes of DEmiRNAs and miRNA&#x02013;mRNA interaction pairs. The R package &#x0201c;VennDiagram&#x0201d; was used to compare the target genes with the DEmRNAs to obtain overlapping genes.</p></sec><sec id="Sec6"><title>Survival analysis and ceRNA network construction</title><p id="Par33">RNA expression profiles and related clinical information of the CRC patients were acquired from TCGA database. To identify lncRNAs significantly associated with patient prognosis, we used the R package &#x0201c;survival&#x0201d; to perform Kaplan-Meier curve analysis of DElncRNAs. DElncRNAs with <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 were considered to be key lncRNAs for construction of the next network. Based on the hypothesis that lncRNA acts as a miRNA sponge to regulate mRNA expression [<xref ref-type="bibr" rid="CR7">7</xref>], we selected key lncRNAs and lncRNA&#x02013;miRNA&#x02013;mRNA interaction pairs to build the ceRNA regulatory network. Ultimately, we combined specific lncRNA&#x02013;miRNA and miRNA&#x02013;mRNA pairs to establish a prognosis-related network. The established ceRNA network was visualized using Cytoscape v3.6.0 software [<xref ref-type="bibr" rid="CR18">18</xref>]. Univariate and multivariate Cox regression analyses were performed to identify the independent prognostic indicators for overall survival (OS).</p></sec><sec id="Sec7"><title>Construction of PPI network</title><p id="Par34">To better understand the interactions of DEmRNAs in the ceRNA network, we constructed a PPI network using the Search Tool for the Retrieval of Interacting Genes (STRING; <ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>) [<xref ref-type="bibr" rid="CR19">19</xref>] database. The median confidence score (0.4) was used to filter protein interactions. Cytoscape 3.6.0 was used to embody the constructed PPI networks. In addition, we used the plugin cytoHubba to identify hub genes in the PPI network according to degree of connectivity. The top 30 hub genes were identified through the Degree ranking method. The MCODE plugin was used to analyze the PPI network and select the top module for subnetwork analysis.</p></sec><sec id="Sec8"><title>Functional annotation analysis</title><p id="Par35">To explore the potential biological functions and pathways of mRNAs in the ceRNA and module network, we performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis through the R package &#x0201c;ClusterProfiler&#x0201d;. GO terms and KEGG pathways with <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 were considered significantly enriched.</p></sec><sec id="Sec9"><title>Clinical feature analysis of key lncRNAs</title><p id="Par36">Clinical information, including age, sex, tumor stage, and TNM stage, was extracted from TCGA database. Based on the prognosis-related ceRNA network, we evaluated the associations between key lncRNAs and the clinical features of CRC patients using the R package &#x0201c;ggpubr&#x0201d;.</p></sec><sec id="Sec10"><title>Correlation analysis of lncRNAs and mRNAs</title><p id="Par37">We performed Pearson correlation analysis and selected the positive correlations between the lncRNAs and mRNAs in ceRNA network. Pearson correlation coefficient&#x02009;&#x0003e;&#x02009;0.4 and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 were used as inclusion criteria. Based on the above co-expression relationships, we constructed a ceRNA subnetwork to investigate the potential mechanisms.</p></sec><sec id="Sec11"><title>Validation of gene expression</title><p id="Par38">Gene Expression Profiling Interactive Analysis (GEPIA; <ext-link ext-link-type="uri" xlink:href="http://gepia.cancer-pku.cn/">http://gepia.cancer-pku.cn/</ext-link>) is an online analysis tool based on TCGA and the Genotype-Tissue Expression (GTEx) dataset [<xref ref-type="bibr" rid="CR20">20</xref>]. Differential expression boxplot in GEPIA was used to compare the expression levels of genes between tumor samples and normal samples. The Human Protein Atlas (THPA; <ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org">https://www.proteinatlas.org</ext-link>) is a database that provides immunohistochemistry-based maps of human protein profiles for cancer tissues and normal tissues and cells [<xref ref-type="bibr" rid="CR21">21</xref>]. We obtained immunohistochemistry images and data from this database to validate gene expression at the protein level. Staining intensity was evaluated as follows: no staining, 0; low staining, 1; medium staining, 2; high staining, 3. Staining quantity was scored as follows: none, 0; &#x0003c;&#x02009;25%, 1; 25&#x02013;50%, 2; 51&#x02013;75%, 3; &#x0003e;&#x02009;75%, 4. The total staining score was calculated by multiplying these two scores. Differences in the total staining scores between normal and CRC tissues were evaluated using the unpaired t-test. <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec><sec id="Sec12"><title>Gene set enrichment analysis</title><p id="Par39">To explore the biological pathways of genes in a subnetwork, Gene Set Enrichment Analysis (GSEA) analysis was performed based on TCGA dataset. According to the cutoff value, the samples were divided into high and low expression phenotypes. The gene set permutations were performed 1000 times per analysis. Gene sets with |normalized enrichment score (NES)|&#x02009;&#x0003e;&#x02009;1 and P&#x02009;&#x0003c;&#x02009;0.05 were considered significantly enriched.</p></sec><sec id="Sec13"><title>Evaluation of immune cell infiltration</title><p id="Par40">Normalized gene expression data were uploaded to TIMER2.0 (<ext-link ext-link-type="uri" xlink:href="http://timer.cistrome.org/">http://timer.cistrome.org/</ext-link>) [<xref ref-type="bibr" rid="CR22">22</xref>], a website that provides comprehensive evaluation and analysis of tumor-infiltrating immune cells, to estimate the relative abundance of 22 immune cell types based on the CIBERSORT algorithm. To evaluate the correlation between lncRNA and immune cell infiltration in the tumor microenvironment, CRC samples from the TCGA database were divided into high and low lncRNA expression groups. The Wilcoxon rank-sum test was performed to compare the differences in immune cell infiltration between the high and low lncRNA expression groups.</p></sec></sec><sec id="Sec14"><title>Results</title><sec id="Sec15"><title>Differentially expressed lncRNAs, miRNAs, and mRNAs</title><p id="Par41">We obtained the expression profiles of 19,645 mRNAs, 14,166 lncRNAs, and 1881 miRNAs from TCGA database. A total of 2480 DEmRNAs, 217 DElncRNAs, and 376 DEmiRNAs were identified with the criteria of |log2 FC|&#x02009;&#x0003e;&#x02009;1 and adjusted <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. Among them, 1325 DEmRNAs, 159 DElncRNAs, and 243 DEmiRNAs were upregulated, whereas 1155 DEmRNAs, 58 DElncRNAs, and 133 DEmiRNAs were downregulated (Supplementary Figure S<xref rid="MOESM1" ref-type="media">1</xref> and Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Volcano plots of differentially expressed RNAs. <bold>a</bold> Volcano plot of lncRNAs. <bold>b</bold> Volcano plot of miRNAs. <bold>c</bold> Volcano plot of mRNAs. The red dots represent upregulated RNAs, and the green dots represent downregulated RNAs</p></caption><graphic xlink:href="12885_2021_7995_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec16"><title>Prediction of lncRNA&#x02013;miRNA and miRNA&#x02013;mRNA interactions</title><p id="Par42">We predicted lncRNA&#x02013;miRNA interaction pairs based on DElncRNAs using the online tool DIANA-LncBase version 3 and found that 153 of the 217 DElncRNAs might target 199 of the 376 DEmiRNAs. Subsequently, miRTarBase, miRDB, and TargetScan databases were used to identify miRNA&#x02013;mRNA interaction pairs. Target mRNAs that were recognized by all three databases were selected as candidate genes. The results showed that 184 of the 199 specific DEmiRNAs might target 3475 candidate genes. After comparing the 3475 candidate genes with 2480 DEmRNAs, we obtained 455 overlapping genes and 1148 miRNA&#x02013;mRNA interaction pairs.</p></sec><sec id="Sec17"><title>Construction of prognosis-related ceRNA network</title><p id="Par43">A ceRNA network was constructed using 2489 lncRNA-miRNA pairs and 1148 miRNA-mRNA pairs using Cytoscape software. The association of 153 lncRNAs in the ceRNA network with patient prognosis was analyzed using Kaplan-Meier survival curves. The results showed that 11 of the 153 lncRNAs were significantly associated with OS. The 11 prognosis-related DElncRNAs were considered key lncRNAs. LINC02038 and AC104823.1 were positively correlated with OS, whereas MIR4435-2HG, NKILA, AFAP1-AS1, ELFN1-AS1, AC005520.2, AC245884.8, AL354836.1, AL355987.4, and AL591845.1 were negatively correlated with OS (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Ultimately, we constructed a survival-related ceRNA network with 11 key lncRNAs, 54 DEmiRNAs, and 308 DEmRNAs. This network contained 373 nodes and 739 edges (Supplementary Figure S<xref rid="MOESM2" ref-type="media">2</xref>). A total of 11 lncRNAs and 308 mRNAs in the ceRNA network were included in the univariate cox regression analysis. Six lncRNAs and 28 mRNAs with <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 were subjected to multivariate COX regression analysis. The lncRNA ELFN1-AS1 and the SPTBN2, CCNF, and VEGFA mRNAs were identified as independent prognostic factors for OS in CRC patients (Supplementary Table S<xref rid="MOESM3" ref-type="media">3</xref>).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Kaplan-Meier survival curves of eleven key lncRNAs related to overall survival (OS). LINC02038 (<bold>a</bold>) and AC104823.1 (<bold>b</bold>) were positively correlated with OS. MIR4435-2HG (<bold>c</bold>), ELFN1-AS1 (<bold>d</bold>), NKILA (<bold>e</bold>), AFAP1-AS1 (<bold>f</bold>), AL591845.1 (<bold>g</bold>), AL355987.4 (<bold>h</bold>), AL354836.1 (<bold>i</bold>), AC005520.2 (<bold>j</bold>), and AC245884.8 (<bold>k</bold>) were negatively correlated with OS. The red lines represent the high expression groups, and the blue lines represent the low expression groups</p></caption><graphic xlink:href="12885_2021_7995_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec18"><title>PPI network and module analysis</title><p id="Par44">The mRNAs in the ceRNA network were used to construct a PPI network based on the STRING database. The PPI network was visualized by Cytoscape and included 265 nodes and 1109 edges (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). The cytoHubba plugin was used to identify the top 30 hub genes with the highest degrees (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>), of which 7 genes (VEGFA, BIRC5, CDC25A, KPNA2, DLGAP5, CCNE1, and CCNF) were significantly related to OS using Kaplan-Meier analysis (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The MCODE plugin was used in the PPI network to identify the top module, which contained 31 nodes and 341 PPIs (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>a).
<fig id="Fig4"><label>Fig. 4</label><caption><p>The protein&#x02013;protein interaction (PPI) network of differentially expressed genes in the prognosis-related ceRNA network. Each node corresponds to a protein-coding gene, and the size of the node represents the connection degree</p></caption><graphic xlink:href="12885_2021_7995_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Top 30 hub genes in the PPI network</p></caption><table frame="hsides" rules="groups"><thead><tr><th>mRNA</th><th>Degree</th><th>Expression</th><th>mRNA</th><th>Degree</th><th>Expression</th><th>mRNA</th><th>Degree</th><th>Expression</th></tr></thead><tbody><tr><td>MYC</td><td>65</td><td>up</td><td>RRM2</td><td>32</td><td>up</td><td>CCNE1</td><td>25</td><td>up</td></tr><tr><td>VEGFA</td><td>54</td><td>up</td><td>CDC25A</td><td>30</td><td>up</td><td>CEP55</td><td>25</td><td>up</td></tr><tr><td>CCND1</td><td>45</td><td>up</td><td>CDKN1A</td><td>30</td><td>down</td><td>RACGAP1</td><td>24</td><td>up</td></tr><tr><td>EZH2</td><td>45</td><td>up</td><td>PCNA</td><td>30</td><td>up</td><td>ESPL1</td><td>24</td><td>up</td></tr><tr><td>CCNB1</td><td>44</td><td>up</td><td>KPNA2</td><td>29</td><td>up</td><td>RAD51AP1</td><td>24</td><td>up</td></tr><tr><td>CCNA2</td><td>42</td><td>up</td><td>E2F1</td><td>29</td><td>up</td><td>E2F7</td><td>24</td><td>up</td></tr><tr><td>CHEK1</td><td>40</td><td>up</td><td>DLGAP5</td><td>28</td><td>up</td><td>CCNF</td><td>23</td><td>up</td></tr><tr><td>MCM7</td><td>37</td><td>up</td><td>KIF23</td><td>28</td><td>up</td><td>CLSPN</td><td>22</td><td>up</td></tr><tr><td>MKI67</td><td>34</td><td>up</td><td>MYBL2</td><td>28</td><td>up</td><td>KAT2B</td><td>20</td><td>down</td></tr><tr><td>BIRC5</td><td>32</td><td>up</td><td>TRIP13</td><td>28</td><td>up</td><td>MET</td><td>20</td><td>up</td></tr></tbody></table></table-wrap><fig id="Fig5"><label>Fig. 5</label><caption><p>Kaplan-Meier survival curves of seven hub genes related to overall survival (OS). CDC25A (<bold>a</bold>), BIRC5 (<bold>b</bold>), CCNE1 (<bold>c</bold>), CCNF (<bold>d</bold>), DLGAP5 (<bold>e</bold>), and KPNA2 (<bold>f</bold>) were positively correlated with OS, and VEGFA (<bold>g</bold>) was negatively correlated with OS. The red lines represent the high expression groups, and the blue lines represent the low expression groups</p></caption><graphic xlink:href="12885_2021_7995_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Fig. 6</label><caption><p>The identification and analysis of the module network. <bold>a</bold> The top modules selected from the PPI network using the plugin MCODE. <bold>b</bold> GO enrichment analysis of genes in the module network. Genes are shown on the left side of the chord diagram and enriched GO terms are shown on the right side. Red bars represent upregulated genes and blue bars represent downregulated genes</p></caption><graphic xlink:href="12885_2021_7995_Fig6_HTML" id="MO6"/></fig></p></sec><sec id="Sec19"><title>GO and KEGG enrichment analysis of DEmRNAs in ceRNA</title><p id="Par45">We performed GO and KEGG enrichment analysis on 308 mRNAs in the ceRNA network and 31 mRNAs in the module network with the R package &#x0201c;ClusterProfiler&#x0201d;. GO functional enrichment analysis suggested that mRNAs in the ceRNA network were significantly enriched in &#x0201c;proximal promoter sequence-specific DNA binding&#x0201d;, &#x0201c;transcription coregulator activity&#x0201d;, and &#x0201c;RNA polymerase II proximal promoter sequence-specific DNA binding&#x0201d; (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a). KEGG pathway analysis showed that ceRNA-related mRNAs were enriched in &#x0201c;microRNAs in cancer&#x0201d;, &#x0201c;cell cycle&#x0201d;, and &#x0201c;PI3K-Akt signaling pathway&#x0201d; (Fig. <xref rid="Fig7" ref-type="fig">7</xref>b). Enrichment analysis of mRNAs in the module network showed that the enriched GO terms included &#x0201c;microtubule binding&#x0201d;, &#x0201c;cyclin-dependent protein serine/threonine kinase regulator activity&#x0201d;, and &#x0201c;tubulin binding&#x0201d;, whereas the most enriched KEGG pathways were &#x0201c;cell cycle&#x0201d;, &#x0201c;cellular senescence&#x0201d;, and &#x0201c;p53 signaling pathway&#x0201d; (Fig. <xref rid="Fig6" ref-type="fig">6</xref>b and Fig. <xref rid="Fig7" ref-type="fig">7</xref>c).
<fig id="Fig7"><label>Fig. 7</label><caption><p>GO and KEGG enrichment analysis of genes in the ceRNA and module networks. <bold>a</bold> GO enrichment analysis of genes in the ceRNA network. <bold>b</bold> KEGG enrichment analysis of genes in the ceRNA network. <bold>c</bold> KEGG enrichment analysis of genes in the module network</p></caption><graphic xlink:href="12885_2021_7995_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec20"><title>Clinical feature analysis of key lncRNAs</title><p id="Par46">To further investigate the 11 prognosis-related lncRNAs in the ceRNA network, we analyzed the correlation between lncRNAs and clinical features, including age, sex, tumor stage, and TNM stage. Seven lncRNAs were associated with the clinical features of CRC patients (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05). Four lncRNAs&#x02014;NKILA, AC005520.2, AC245884.8, and AL354836.1&#x02014;were age-related, four lncRNAs&#x02014;MIR4435-2HG, NKILA, AL591845.1, and AC005520.2&#x02014;were associated with tumor stage, and six lncRNAs&#x02014;MIR4435-2HG, ELFN1-AS1, NKILA, AL591845.1, AC005520.2, and AL354836.1&#x02014;were associated with TNM stage (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). The detailed clinical and pathological characteristics of 548 colorectal cancer patients are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.
<fig id="Fig8"><label>Fig. 8</label><caption><p>Clinical feature analysis of eleven key lncRNAs. <bold>a</bold> Correlations of lncRNA expression with age. <bold>b</bold> Correlations of lncRNA expression with tumor stage. <bold>c</bold> Correlations of lncRNA expression with pathologic N stage. <bold>d</bold> Correlations of lncRNA expression with pathologic M stage</p></caption><graphic xlink:href="12885_2021_7995_Fig8_HTML" id="MO8"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Clinicopathological characteristics of 548 colorectal carcinoma patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Subtype</th><th>Patients (%)</th></tr></thead><tbody><tr><td rowspan="2">Age (years)</td><td>&#x0003e;&#x02009;65</td><td>311 (56.8%)</td></tr><tr><td>&#x02264;65</td><td>237 (43.2%)</td></tr><tr><td rowspan="2">Gender</td><td>Male</td><td>292 (53.3%)</td></tr><tr><td>Female</td><td>256 (46.7%)</td></tr><tr><td rowspan="5">Pathologic stage</td><td>Stage I</td><td>96 (17.5%)</td></tr><tr><td>Stage II</td><td>210 (38.3%)</td></tr><tr><td>Stage III</td><td>149 (27.2%)</td></tr><tr><td>Stage IV</td><td>78 (14.2%)</td></tr><tr><td>Unknown</td><td>15 (2.7%)</td></tr><tr><td rowspan="5">Pathologic T</td><td>T1</td><td>15 (2.7%)</td></tr><tr><td>T2</td><td>96 (17.5%)</td></tr><tr><td>T3</td><td>373 (68.1%)</td></tr><tr><td>T4</td><td>63 (11.5%)</td></tr><tr><td>Tis</td><td>1 (0.2%)</td></tr><tr><td rowspan="4">Pathologic N</td><td>N0</td><td>323 (58.9%)</td></tr><tr><td>N1</td><td>130 (23.7%)</td></tr><tr><td>N2</td><td>94 (17.2%)</td></tr><tr><td>NX</td><td>1 (0.2%)</td></tr><tr><td rowspan="4">Pathologic M</td><td>M0</td><td>408 (74.5%)</td></tr><tr><td>M1</td><td>77 (14.1%)</td></tr><tr><td>MX</td><td>55 (10.0%)</td></tr><tr><td>Unknown</td><td>8 (1.5%)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec21"><title>Co-expression analysis of lncRNAs and mRNAs</title><p id="Par47">To verify the hypothesis that lncRNA positively regulates mRNA expression by interacting with miRNA in the ceRNA network, we performed Pearson correlation analysis between seven clinically relevant lncRNAs and their target mRNAs. The results showed that MIR4435-2HG was positively correlated with 15 mRNAs (r&#x02009;&#x0003e;&#x02009;0.4, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), of which COL5A2, LOX, OSBPL3, PLAU, and VCAN had a significantly positive correlation with MIR4435-2HG (r&#x02009;&#x0003e;&#x02009;0.5). We speculated that MIR4435-2HG upregulated the expression of the above five DEmRNAs through different DEmiRNAs (mir-29a, mir-424, mir-335, mir-193a, and mir-193a) (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>a-f). Our correlation analysis of ELFN1-AS1 showed that seven mRNAs were positively associated with ELFN1-AS1 (r&#x02009;&#x0003e;&#x02009;0.4, Table <xref rid="Tab3" ref-type="table">3</xref>), whereas SRM and E2F1 had a significantly positive correlation with ELFN1-AS1 (r&#x02009;&#x0003e;&#x02009;0.5). Based on the ceRNA hypothesis, ELFN1-AS1 may upregulate the expression of SRM and E2F1 by acting as sponges of mir-423 and mir-93, respectively (Fig. <xref rid="Fig9" ref-type="fig">9</xref>g-i).
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Positive correlations between lncRNAs and mRNAs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>lncRNA</th><th>mRNA</th></tr></thead><tbody><tr><td>MIR4435-2HG</td><td>COL5A2, LOX, OSBPL3, PLAU, VCAN, ANGPT2, CBFB, COL3A1, COL4A1, EIF5A2, GPR180, RGS16, SLC7A11, TM4SF18, VMA21</td></tr><tr><td>ELFN1-AS1</td><td>E2F1, SRM, BIRC5, C20orf27, DUSP2, LMNB2, MYBL2</td></tr><tr><td>AL354836.1</td><td>FGFRL1</td></tr><tr><td>AC245884.8</td><td>VEGFA</td></tr></tbody></table></table-wrap><fig id="Fig9"><label>Fig. 9</label><caption><p>Pearson correlation analysis between lncRNAs and mRNAs. <bold>a</bold>&#x02013;<bold>e</bold> The co-expression relationship between MIR4435-2HG and paired mRNAs (PLAU, LOX, COL5A1, VCAN and OSBPL3). <bold>f</bold> The ceRNA regulatory subnetwork of MIR4435-2HG. (G&#x02013;H) The co-expression relationship between ELFN1-AS1 and paired mRNAs (SRM and E2F1). <bold>i</bold> The ceRNA regulatory subnetwork of ELFN1-AS1</p></caption><graphic xlink:href="12885_2021_7995_Fig9_HTML" id="MO9"/></fig></p></sec><sec id="Sec22"><title>Validation of gene expression by GEPIA and immunohistochemistry</title><p id="Par48">We used TCGA and GTEx datasets in GEPIA to further validate the differential expression of genes between tumor and normal samples. The expression levels of PLAU, OSBPL3, LOX, VCAN, E2F1, and SRM were upregulated in COAD and READ tissues compared with normal tissues (all <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref>). However, the expression of COL5A2 showed no differential expression between tumor and normal tissues. Immunohistochemistry results were obtained from the THPA database, and the staining scores were quantified to verify the protein expression levels of the genes. The staining scores for SRM (<italic>P</italic>&#x02009;=&#x02009;0.0015), OSBPL3 (<italic>P</italic>&#x02009;=&#x02009;0.0263), and VCAN (<italic>P</italic>&#x02009;=&#x02009;0.0229) were higher in the CRC tissue than normal tissue, whereas PLAU (<italic>P</italic>&#x02009;=&#x02009;0.0169) showed the opposite pattern. There was no significant difference between the E2F1 staining scores (<italic>P</italic>&#x02009;=&#x02009;0.6213) for CRC and normal tissue (Fig.&#x000a0;<xref rid="Fig11" ref-type="fig">11</xref>).
<fig id="Fig10"><label>Fig. 10</label><caption><p>Validation of differential gene expression using Gene Expression Profiling Interactive Analysis (GEPIA). The red bars represent tumor samples, and the gray bars represent normal samples</p></caption><graphic xlink:href="12885_2021_7995_Fig10_HTML" id="MO10"/></fig><fig id="Fig11"><label>Fig. 11</label><caption><p>Immunohistochemical analysis of protein expression levels of genes based on The Human Protein Atlas (THPA) database. <bold>a</bold> Immunohistochemical results for normal tissues. <bold>b</bold> Immunohistochemical results for CRC tissues. <bold>c</bold> Plot diagram of staining scores between CRC and normal tissues</p></caption><graphic xlink:href="12885_2021_7995_Fig11_HTML" id="MO11"/></fig></p></sec><sec id="Sec23"><title>GSEA-predicted biological functions of genes</title><p id="Par49">We used GSEA analysis to predict the enriched KEGG pathways between high and low expressions of genes in a subnetwork. PLAU, encoding a secreted serine protease, was positively correlated with &#x0201c;extracellular matrix&#x0201d;, &#x0201c;angiogenesis&#x0201d;, and &#x0201c;serine hydrolase activity&#x0201d;. LOX was significantly enriched in &#x0201c;extracellular matrix&#x0201d;, &#x0201c;cell adhesion molecule binding&#x0201d;, and &#x0201c;angiogenesis&#x0201d;. VCAN belongs to the aggrecan/versican proteoglycan family, which was positively correlated with &#x0201c;extracellular matrix component&#x0201d;, &#x0201c;cell adhesion molecule binding&#x0201d;, and &#x0201c;proteoglycan metabolic process&#x0201d;. COL5A2 encodes one alpha chain of fibrillar collagen trimers. The high expression of COL5A2 was correlated with &#x0201c;extracellular matrix&#x0201d;, &#x0201c;collagen trimer&#x0201d;, and &#x0201c;collagen fibril organization&#x0201d;, whereas E2F1 was negatively correlated with &#x0201c;biological adhesion&#x0201d;, &#x0201c;regulation of cell adhesion&#x0201d;, and &#x0201c;cell motility&#x0201d; (Fig.&#x000a0;<xref rid="Fig12" ref-type="fig">12</xref>).
<fig id="Fig12"><label>Fig. 12</label><caption><p>Gene set enrichment analysis (GSEA) revealed enriched KEGG pathways based on gene expression levels</p></caption><graphic xlink:href="12885_2021_7995_Fig12_HTML" id="MO12"/></fig></p></sec><sec id="Sec24"><title>Tumor-infiltrating immune cells in CRC</title><p id="Par50">A cohort of 568 CRC patients was divided into high and low expression groups based on lncRNA expression. The results of the Wilcoxon rank-sum test revealed that plasma B cells (<italic>P</italic>&#x02009;=&#x02009;0.001) and CD4+ memory resting T cells (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) were greater in patients with low MIR4435-2HG expression, while follicular helper T cells (<italic>P</italic>&#x02009;=&#x02009;0.037) and neutrophils (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) were greater in patients with high MIR4435-2HG expression (Fig.&#x000a0;<xref rid="Fig13" ref-type="fig">13</xref>a). The high ELFN1-AS1 expression group had significantly higher numbers of plasma B cells (<italic>P</italic>&#x02009;=&#x02009;0.039), CD4+ memory-activated T cells (<italic>P</italic>&#x02009;=&#x02009;0.006), gamma delta T cells (<italic>P</italic>&#x02009;=&#x02009;0.007), monocytes (<italic>P</italic>&#x02009;=&#x02009;0.047), and resting myeloid dendritic cells (<italic>P</italic>&#x02009;=&#x02009;0.031). The low ELFN1-AS1 expression group had higher numbers of CD8+ T cells (<italic>P</italic>&#x02009;=&#x02009;0.001) and neutrophils (<italic>P</italic>&#x02009;=&#x02009;0.024) (Fig.&#x000a0;<xref rid="Fig13" ref-type="fig">13</xref>b). Correlation analysis was performed to determine the co-expression patterns among 22 tumor-infiltrating immune cell types (Supplementary Figure S<xref rid="MOESM4" ref-type="media">4</xref>).
<fig id="Fig13"><label>Fig. 13</label><caption><p>Violin plots for tumor-infiltrating immune cells. <bold>a</bold> Comparison of immune cell proportions between high and low MIR4435-2HG expression groups. <bold>b</bold> Comparison of immune cell proportions between high and low ELFN1-AS1 expression groups. The blue bars represent the low expression groups, and the red bars represent the high expression groups</p></caption><graphic xlink:href="12885_2021_7995_Fig13_HTML" id="MO13"/></fig></p></sec></sec><sec id="Sec25"><title>Discussion</title><p id="Par51">Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Increasing evidence has shown that dysregulated lncRNAs or lncRNA-mediated ceRNA networks are involved in the progression and prognosis of the CRC. LncRNAs suppress miRNA-induced translational inhibition of gene expression by competitively binding to miRNA response elements. In recent years, they have gained wide attention due to their important roles in tumor progression, patient prognosis, and immune infiltration [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. The lncRNA H19/miR-29b-3p/PGRN axis promotes EMT in CRC and counts a great deal for seeking appropriate diagnostic biomarkers and therapeutic targets for CRC [<xref ref-type="bibr" rid="CR11">11</xref>]. The oncogenic HOTAIR/miR-331-3p/HER2 axis is associated with tumor progression and poor prognosis in gastric cancer [<xref ref-type="bibr" rid="CR24">24</xref>]. In addition, the RP11-1094&#x02009;M14.8/miR-1269a/CXCL9 axis is a potential prognostic marker for gastric cancer with different degrees of immune cell infiltration [<xref ref-type="bibr" rid="CR13">13</xref>]. Thus, identifying lncRNAs and their associated ceRNA networks as prognostic factors may provide a foundation for the development of early diagnostic biomarkers and therapeutic targets in CRC.</p><p id="Par52">In this study, we analyzed TCGA sequence data from CRC patients and constructed a prognostic ceRNA network to explore the potential function of lncRNAs and their related genes. MIR4435-2HG and ELFN1-AS1 were identified as potential prognostic biomarkers and therapeutic targets in CRC based on survival and clinical feature analysis. MIR4435-2HG promotes CRC growth and metastasis through the miR-206/YAP1 axis and predicts poor prognosis in CRC patients [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. ELFN1-AS1 is elevated in CRC tissues, and its upregulation promotes CRC cell proliferation and migration and inhibits apoptosis by competing with the endogenous miR-4644/TRIM44 axis [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. While downregulation of ELFN1-AS1 suppresses the activation of extracellular signal-regulated protein kinase (ERK), decreases vimentin expression, and increases E-cadherin expression.</p><p id="Par53">Based on these ceRNA networks and lncRNA-mRNA co-expression relationships, we obtained two novel ceRNA regulatory subnetworks for MIR4435-2HG and ELFN1-AS1. According to the univariate and multivariate Cox analysis, ELFN1-AS1 was identified as an independent prognostic factor for CRC patients. MIR4435-2HG positively regulated PLAU, VCAN, LOX, COL5A2, and OSBPL3 mRNA expression by acting as a miRNA sponge. PLAU upregulation in primary tumor tissues is positively correlated with distant metastasis and indicates poor patient prognosis in CRC [<xref ref-type="bibr" rid="CR30">30</xref>]. MiR-193a inhibits CRC cell growth and progression partly by downregulating the expression of target gene PLAU, which is consistent with our prediction of PLAU/miR-193a interaction [<xref ref-type="bibr" rid="CR31">31</xref>]. VCAN is overexpressed in various human malignancies, including CRC [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>], and CRC patients with high VCAN expression have worse disease outcomes than those with lower expression [<xref ref-type="bibr" rid="CR38">38</xref>]. Upregulation of LOX expression is correlated with the progression and metastasis of various solid tumors [<xref ref-type="bibr" rid="CR39">39</xref>]. There have been contradictory reports regarding the role of LOX in CRC. Csiszar et al. [<xref ref-type="bibr" rid="CR40">40</xref>] reported that reduced LOX expression in colon tumor tissue supports the function of LOX as a tumor suppressor gene. However, recent studies found that LOX expression was significantly increased in tumor tissue and correlated with poor clinical outcomes of CRC patients [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. COL5A2 is upregulated in CRC tissue compared to normal tissue, suggesting that COL5A2 is involved in CRC carcinogenesis [<xref ref-type="bibr" rid="CR43">43</xref>]; however, there are no reports about the role of OSBPL3 in CRC. E2F1 and SRM were predicted to be co-expressed genes involved in the ELFN1-AS1 regulatory network. Several studies have demonstrated that E2F1 is an oncogene involved in CRC proliferation and metastasis. Higher E2F1 expression levels indicate a shorter OS in CRC patients [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. However, there is also evidence to support E2F1 as a tumor suppressor gene involved in the induction of apoptosis in CRC [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. SRM encodes one of the key enzymes in the polyamine biosynthesis pathway. Polyamines are essential for cell proliferation and growth, and high expression of polyamines has been linked to several tumors, including CRC [<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR52">52</xref>]. However, the direct correlation between the expression of SRM and human tumorigenesis remains unclear.</p><p id="Par54">Subsequently, we performed GSEA analysis to explore the enriched biological pathways of the co-expressed genes. Most were enriched in the &#x0201c;extracellular matrix component,&#x0201d; &#x0201c;angiogenesis,&#x0201d; and &#x0201c;cell adhesion molecule binding,&#x0201d; which correlated with cancer pathogenesis. The extracellular matrix (ECM) is the main component of the tumor microenvironment and is composed of proteins, glycoproteins, proteoglycans, and polysaccharides [<xref ref-type="bibr" rid="CR53">53</xref>]. Disorders in the ECM structure and composition promote cellular transformation and metastasis during cancer progression [<xref ref-type="bibr" rid="CR54">54</xref>]. Angiogenesis is the formation of new blood vessels from existing vasculature, an important event in tumor growth, invasion into surrounding tissue, and distant metastasis [<xref ref-type="bibr" rid="CR55">55</xref>]. Inhibition of angiogenesis has been a valuable therapeutic strategy for many solid tumors. Cell adhesion molecules (CAMs) play an important role in the interaction of cells with other cells and their surrounding intercellular environment. The role of CAMs in cancer involves angiogenesis, disruption of tissue architecture, and loss of contact with other cells and the ECM [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par55">Tumor-infiltrating immune cells (TIICs) include T cells, dendritic cells (DCs), B cells, macrophages, neutrophils, mast cells, and natural killer (NK) cells. They are major components of the complex microenvironment that regulates tumor progression and predicts prognosis in CRC [<xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>]. To further explore the immune infiltration-related mechanism of how ceRNA regulates CRC prognosis, the estimated proportions of 22 tumor-infiltrating immune cell types in CRC were evaluated by CIBERSORT analysis based on MIR4435-2HG and ELFN1-AS1 expression levels. Our results revealed that nine immune cell types, including CD4+ memory resting T cells, CD4+ memory activated T cells, CD8+ T cells, gamma delta T cells, follicular helper T cells, plasma B cells, neutrophils, monocytes, and resting myeloid DCs, showed statistical differences between the high and low expression groups. Several recent studies reported that the type, density, and location of tumor-infiltrating immune cells are associated with favorable outcomes in CRC [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. The densities of CD4+ and CD8&#x02009;+&#x02009;memory T cells were negatively correlated with local tumor invasion based on the T stage of the TNM classification [<xref ref-type="bibr" rid="CR59">59</xref>]. DCs are potent antigen-presenting cells that play an important role in initiating, programming, and regulating antitumor immune responses. DC-based immunotherapy has been used as anti-cancer immunotherapy to treat various cancers, including CRC [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. The peripheral neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) are prognostic factors for CRC patients [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. The association of MIR4435-2HG and ELFN1-AS1 lncRNA expression with tumor-infiltrating immune cell types supports their role as valuable prognostic markers and immunotherapeutic targets in CRC.</p><p id="Par56">Nevertheless, there are still some limitations to the present study. First, the data used in this study were mainly from Western countries and lacked data from the Asian population. Second, the number of normal cases was relatively small, and a larger number of paired samples are needed for further analysis. Third, the multiple sources of the online verification data need to be further confirmed by homogeneous research samples and systematic experimental studies. For example, although the immunohistochemistry data were extracted from The Human Protein Atlas (THPA) to verify the upregulation of the identified genes in CRC at the protein level, the exact molecular mechanisms involving these hub genes have not been experimentally investigated in the present study. In addition, we observed opposing PLAU expression patterns at the mRNA and protein levels (Fig.&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref> and Fig.&#x000a0;<xref rid="Fig11" ref-type="fig">11</xref>), which is inconsistent with previous reports [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. Taken together, further experimental studies based on a larger sample size are needed to verify our hypotheses.</p></sec><sec id="Sec26"><title>Conclusions</title><p id="Par57">The regulatory networks of MIR4435-2HG and ELFN1-AS1 are considered to be closely associated with CRC prognosis. Although further functional experiments are required, our findings contribute to the development of MIR4435-2HG and ELFN1-AS1 as potential prognostic biomarkers and therapeutic targets in CRC.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec27"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2021_7995_MOESM1_ESM.docx"><caption><p><bold>Additional file 1.</bold> Clustered heatmaps of differentially expressed RNAs. (A) Heatmaps of lncRNAs. (B) Heatmaps of miRNAs. (C) Heatmaps of mRNAs.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12885_2021_7995_MOESM2_ESM.docx"><caption><p><bold>Additional file 2.</bold> Construction of a survival-related ceRNA network. Red nodes represent the upregulated RNAs, and blue nodes represent the downregulated RNAs.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12885_2021_7995_MOESM3_ESM.docx"><caption><p><bold>Additional file 3.</bold> Univariate and multivariable Cox regression analysis of RNAs involved in the ceRNA network.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12885_2021_7995_MOESM4_ESM.docx"><caption><p><bold>Additional file 4.</bold> Correlation of 22 tumor-infiltrating immune cell types.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12885_2021_7995_MOESM5_ESM.docx"><caption><p><bold>Additional file 5.</bold> Certificate of English copyediting service.</p></caption></media></supplementary-material></p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>lncRNA</term><def><p id="Par5">Long noncoding RNA</p></def></def-item><def-item><term>miRNA</term><def><p id="Par6">MicroRNA</p></def></def-item><def-item><term>mRNA</term><def><p id="Par7">Message RNA</p></def></def-item><def-item><term>ceRNA</term><def><p id="Par8">Competing endogenous RNA</p></def></def-item><def-item><term>TCGA</term><def><p id="Par9">The Cancer Genome Atlas</p></def></def-item><def-item><term>DElncRNA</term><def><p id="Par10">Differentially expressed lncRNA</p></def></def-item><def-item><term>DEmiRNA</term><def><p id="Par11">Differentially expressed miRNA</p></def></def-item><def-item><term>DEmRNA</term><def><p id="Par12">Differentially expressed mRNA</p></def></def-item><def-item><term>GEPIA</term><def><p id="Par13">Gene Expression Profiling Interactive Analysis</p></def></def-item><def-item><term>GSEA</term><def><p id="Par14">Gene Set Enrichment Analysis</p></def></def-item><def-item><term>CRC</term><def><p id="Par15">Colorectal cancer</p></def></def-item><def-item><term>OS</term><def><p id="Par16">Overall survival</p></def></def-item><def-item><term>EMT</term><def><p id="Par17">Epithelial-to-mesenchymal transition</p></def></def-item><def-item><term>PPI</term><def><p id="Par18">Protein&#x02013;protein interaction</p></def></def-item><def-item><term>GO</term><def><p id="Par19">Gene Ontology</p></def></def-item><def-item><term>KEGG</term><def><p id="Par20">Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term>STRING</term><def><p id="Par21">Search Tool for the Retrieval of Interacting Genes</p></def></def-item><def-item><term>GTEx</term><def><p id="Par22">Genotype-Tissue Expression</p></def></def-item><def-item><term>THPA</term><def><p id="Par23">The Human Protein Atlas</p></def></def-item><def-item><term>NES</term><def><p id="Par24">Normalized enrichment score</p></def></def-item><def-item><term>COAD</term><def><p id="Par25">Colon adenocarcinoma</p></def></def-item><def-item><term>READ</term><def><p id="Par26">Rectal adenocarcinoma</p></def></def-item><def-item><term>ERK</term><def><p id="Par27">Extracellular-signal regulated protein kinase</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Jingzhu Guo and Weidong Yu contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the editors from BioMed Proofreading LLC for comprehensive editing of this manuscript (Additional&#x000a0;file&#x000a0;<xref rid="MOESM5" ref-type="media">5</xref>).</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>JYC, YXS, and WDY designed the study. ML, YZ, and TRL downloaded and analyzed data. JYC, JS, and DW wrote the initial version of the manuscript. YLL, JZG and WDY revised the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was supported by the National Natural Science Foundation of China (Nos. 30872923 and 81672853) and Peking University People&#x02019;s Hospital Scientific Research Development Funds (RDH2020&#x02013;11). The funding bodies had no role in the design of the study, the collection, analysis, or interpretation of data, or the writing of the manuscript.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The data information of this study was obtained from the Cancer Genome Atlas (TCGA; <ext-link ext-link-type="uri" xlink:href="http://cancergenome.nih.gov/">http://cancergenome.nih.gov/</ext-link>), the Human Protein Atlas (THPA; <ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org">https://www.proteinatlas.org</ext-link>) and the GTEx projects.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par58">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par59">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par60">The authors declare that there is no competing interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2018</year><volume>68</volume><issue>6</issue><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekker</surname><given-names>E</given-names></name><name><surname>Tanis</surname><given-names>PJ</given-names></name><name><surname>Vleugels</surname><given-names>J</given-names></name><name><surname>Kasi</surname><given-names>PM</given-names></name><name><surname>Wallace</surname><given-names>MB</given-names></name></person-group><article-title>Colorectal cancer</article-title><source>Lancet</source><year>2019</year><volume>394</volume><issue>10207</issue><fpage>1467</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)32319-0</pub-id><?supplied-pmid 31631858?><pub-id pub-id-type="pmid">31631858</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Molecular mechanisms of long noncoding RNAs</article-title><source>Mol Cell</source><year>2011</year><volume>43</volume><issue>6</issue><fpage>904</fpage><lpage>914</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.08.018</pub-id><?supplied-pmid 21925379?><pub-id pub-id-type="pmid">21925379</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>D</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>A feedback loop consisting of RUNX2/LncRNA-PVT1/miR-455 is involved in the progression of colorectal cancer</article-title><source>Am J Cancer Res</source><year>2018</year><volume>8</volume><issue>3</issue><fpage>538</fpage><lpage>550</lpage><?supplied-pmid 29637007?><pub-id pub-id-type="pmid">29637007</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XD</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>YS</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name></person-group><article-title>Functional role of long non-coding RNA CASC19/miR-140-5p/CEMIP axis in colorectal cancer progression in vitro</article-title><source>World J Gastroenterol</source><year>2019</year><volume>25</volume><issue>14</issue><fpage>1697</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.3748/wjg.v25.i14.1697</pub-id><?supplied-pmid 31011255?><pub-id pub-id-type="pmid">31011255</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Cui M, Chen M, Shen Z, Wang R, Fang X, Song B. LncRNA-UCA1 modulates progression of colon cancer through regulating the miR-28-5p/HOXB3 axis. J Cell Biochem. 2019.</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salmena</surname><given-names>L</given-names></name><name><surname>Poliseno</surname><given-names>L</given-names></name><name><surname>Tay</surname><given-names>Y</given-names></name><name><surname>Kats</surname><given-names>L</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name></person-group><article-title>A ceRNA hypothesis: the Rosetta stone of a hidden RNA language?</article-title><source>CELL</source><year>2011</year><volume>146</volume><issue>3</issue><fpage>353</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.07.014</pub-id><?supplied-pmid 21802130?><pub-id pub-id-type="pmid">21802130</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopp</surname><given-names>F</given-names></name><name><surname>Mendell</surname><given-names>JT</given-names></name></person-group><article-title>Functional classification and experimental dissection of long noncoding RNAs</article-title><source>CELL</source><year>2018</year><volume>172</volume><issue>3</issue><fpage>393</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.011</pub-id><?supplied-pmid 29373828?><pub-id pub-id-type="pmid">29373828</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Luan</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name></person-group><article-title>Long noncoding RNA DANCR promotes colorectal cancer proliferation and metastasis via miR-577 sponging</article-title><source>Exp Mol Med</source><year>2018</year><volume>50</volume><issue>5</issue><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s12276-018-0082-5</pub-id><?supplied-pmid 30504803?><pub-id pub-id-type="pmid">30504803</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Pei J, Xiao W, Zhu D, Ji X, Shi L, Deng X. LncRNA DSCAM-AS1 promotes proliferation, migration and invasion of colorectal Cancer cells via modulating miR-144-5p/CDKL1. Life Sci. 2019;117050.</mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>LncRNA H19/miR-29b-3p/PGRN Axis promoted epithelial-Mesenchymal transition of colorectal Cancer cells by acting on Wnt signaling</article-title><source>Mol Cells</source><year>2018</year><volume>41</volume><issue>5</issue><fpage>423</fpage><lpage>435</lpage><?supplied-pmid 29754471?><pub-id pub-id-type="pmid">29754471</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>DL</given-names></name><name><surname>Lu</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>JX</given-names></name><name><surname>Wei</surname><given-names>XL</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Zeng</surname><given-names>ZL</given-names></name><name><surname>Pan</surname><given-names>ZZ</given-names></name><name><surname>Yuan</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>FH</given-names></name><name><surname>Pelicano</surname><given-names>H</given-names></name><etal/></person-group><article-title>Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression</article-title><source>THERANOSTICS</source><year>2017</year><volume>7</volume><issue>19</issue><fpage>4836</fpage><lpage>4849</lpage><pub-id pub-id-type="doi">10.7150/thno.20942</pub-id><?supplied-pmid 29187907?><pub-id pub-id-type="pmid">29187907</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Mi</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name></person-group><article-title>A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration</article-title><source>Cancer Sci</source><year>2020</year><volume>111</volume><issue>11</issue><fpage>4041</fpage><lpage>4050</lpage><pub-id pub-id-type="doi">10.1111/cas.14634</pub-id><?supplied-pmid 32860283?><pub-id pub-id-type="pmid">32860283</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karagkouni</surname><given-names>D</given-names></name><name><surname>Paraskevopoulou</surname><given-names>MD</given-names></name><name><surname>Tastsoglou</surname><given-names>S</given-names></name><name><surname>Skoufos</surname><given-names>G</given-names></name><name><surname>Karavangeli</surname><given-names>A</given-names></name><name><surname>Pierros</surname><given-names>V</given-names></name><name><surname>Zacharopoulou</surname><given-names>E</given-names></name><name><surname>Hatzigeorgiou</surname><given-names>AG</given-names></name></person-group><article-title>DIANA-LncBase v3: indexing experimentally supported miRNA targets on non-coding transcripts</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>D1</issue><fpage>D101</fpage><lpage>D110</lpage><?supplied-pmid 31732741?><pub-id pub-id-type="pmid">31732741</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miRDB: an online resource for microRNA target prediction and functional annotations</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>Database issue</issue><fpage>D146</fpage><lpage>D152</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1104</pub-id><?supplied-pmid 25378301?><pub-id pub-id-type="pmid">25378301</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>SD</given-names></name><name><surname>Lin</surname><given-names>FM</given-names></name><name><surname>Wu</surname><given-names>WY</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name><name><surname>Chan</surname><given-names>WL</given-names></name><name><surname>Tsai</surname><given-names>WT</given-names></name><name><surname>Chen</surname><given-names>GZ</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Chiu</surname><given-names>CM</given-names></name><etal/></person-group><article-title>miRTarBase: a database curates experimentally validated microRNA-target interactions</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>Database issue</issue><fpage>D163</fpage><lpage>D169</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1107</pub-id><pub-id pub-id-type="pmid">21071411</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>BP</given-names></name><name><surname>Shih</surname><given-names>IH</given-names></name><name><surname>Jones-Rhoades</surname><given-names>MW</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name></person-group><article-title>Prediction of mammalian microRNA targets</article-title><source>Cell</source><year>2003</year><volume>115</volume><issue>7</issue><fpage>787</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)01018-3</pub-id><?supplied-pmid 14697198?><pub-id pub-id-type="pmid">14697198</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Ramage</surname><given-names>D</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Schwikowski</surname><given-names>B</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><issue>11</issue><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><?supplied-pmid 403769?><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D</given-names></name><name><surname>Gable</surname><given-names>AL</given-names></name><name><surname>Lyon</surname><given-names>D</given-names></name><name><surname>Junge</surname><given-names>A</given-names></name><name><surname>Wyder</surname><given-names>S</given-names></name><name><surname>Huerta-Cepas</surname><given-names>J</given-names></name><name><surname>Simonovic</surname><given-names>M</given-names></name><name><surname>Doncheva</surname><given-names>NT</given-names></name><name><surname>Morris</surname><given-names>JH</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><etal/></person-group><article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>D1</issue><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="pmid">30476243</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>W1</issue><fpage>W98</fpage><lpage>W102</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id><?supplied-pmid 28407145?><pub-id pub-id-type="pmid">28407145</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>M</given-names></name><name><surname>Fagerberg</surname><given-names>L</given-names></name><name><surname>Hallstrom</surname><given-names>BM</given-names></name><name><surname>Lindskog</surname><given-names>C</given-names></name><name><surname>Oksvold</surname><given-names>P</given-names></name><name><surname>Mardinoglu</surname><given-names>A</given-names></name><name><surname>Sivertsson</surname><given-names>A</given-names></name><name><surname>Kampf</surname><given-names>C</given-names></name><name><surname>Sjostedt</surname><given-names>E</given-names></name><name><surname>Asplund</surname><given-names>A</given-names></name><etal/></person-group><article-title>Proteomics. Tissue-based map of the human proteome</article-title><source>Science</source><year>2015</year><volume>347</volume><issue>6220</issue><fpage>1260419</fpage><pub-id pub-id-type="doi">10.1126/science.1260419</pub-id><?supplied-pmid 25613900?><pub-id pub-id-type="pmid">25613900</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><article-title>TIMER2.0 for analysis of tumor-infiltrating immune cells</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><issue>W1</issue><fpage>W509</fpage><lpage>W514</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa407</pub-id><?supplied-pmid 32442275?><pub-id pub-id-type="pmid">32442275</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tay</surname><given-names>Y</given-names></name><name><surname>Rinn</surname><given-names>J</given-names></name><name><surname>Pandolfi</surname><given-names>PP</given-names></name></person-group><article-title>The multilayered complexity of ceRNA crosstalk and competition</article-title><source>NATURE</source><year>2014</year><volume>505</volume><issue>7483</issue><fpage>344</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1038/nature12986</pub-id><?supplied-pmid 24429633?><pub-id pub-id-type="pmid">24429633</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Nie</surname><given-names>FQ</given-names></name><name><surname>Ge</surname><given-names>YB</given-names></name><name><surname>Zhang</surname><given-names>EB</given-names></name><name><surname>Yin</surname><given-names>DD</given-names></name><name><surname>Kong</surname><given-names>R</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>KH</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer</article-title><source>Mol Cancer</source><year>2014</year><volume>13</volume><fpage>92</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-13-92</pub-id><?supplied-pmid 24775712?><pub-id pub-id-type="pmid">24775712</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name></person-group><article-title>Long non-coding RNA MIR4435-2HG promotes colorectal Cancer proliferation and metastasis through miR-206/YAP1 Axis</article-title><source>Front Oncol</source><year>2020</year><volume>10</volume><fpage>160</fpage><pub-id pub-id-type="doi">10.3389/fonc.2020.00160</pub-id><?supplied-pmid 32154166?><pub-id pub-id-type="pmid">32154166</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>MY</given-names></name><name><surname>Zhou</surname><given-names>GR</given-names></name><name><surname>Y</surname><given-names>ZZ</given-names></name></person-group><article-title>LncRNA MIR4435-2HG contributes into colorectal cancer development and predicts poor prognosis</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2020</year><volume>24</volume><issue>4</issue><fpage>1771</fpage><lpage>1777</lpage><?supplied-pmid 32141545?><pub-id pub-id-type="pmid">32141545</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>W</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Chi</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><article-title>LncRNA MIR4435-2HG predicts poor prognosis in patients with colorectal cancer</article-title><source>Peer J</source><year>2019</year><volume>7</volume><fpage>e6683</fpage><pub-id pub-id-type="doi">10.7717/peerj.6683</pub-id><?supplied-pmid 30972258?><pub-id pub-id-type="pmid">30972258</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Lei R, Feng L, Hong D. ELFN1-AS1 accelerates the proliferation and migration of colorectal cancer via regulation of miR-4644/TRIM44 axis. Cancer Biomark. 2019.</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Kang</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Extracellular vesicles from human umbilical cord mesenchymal stem cells treated with siRNA against ELFN1-AS1 suppress colon adenocarcinoma proliferation and migration</article-title><source>Am J Transl Res</source><year>2019</year><volume>11</volume><issue>11</issue><fpage>6989</fpage><lpage>6999</lpage><?supplied-pmid 31814902?><pub-id pub-id-type="pmid">31814902</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JL</given-names></name><name><surname>Seetoo</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name><name><surname>Berney</surname><given-names>CR</given-names></name><name><surname>Ham</surname><given-names>JM</given-names></name><name><surname>Russell</surname><given-names>PJ</given-names></name><name><surname>Crowe</surname><given-names>PJ</given-names></name></person-group><article-title>Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets</article-title><source>Int J Cancer</source><year>2000</year><volume>89</volume><issue>5</issue><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1002/1097-0215(20000920)89:5&#x0003c;431::AID-IJC6&#x0003e;3.0.CO;2-V</pub-id><?supplied-pmid 11008205?><pub-id pub-id-type="pmid">11008205</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Sheng</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA-193a-3p suppresses the colorectal cancer cell proliferation and progression through downregulating the PLAU expression</article-title><source>Cancer Manag Res</source><year>2019</year><volume>11</volume><fpage>5353</fpage><lpage>5363</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S208233</pub-id><?supplied-pmid 31354344?><pub-id pub-id-type="pmid">31354344</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miquel-Serra</surname><given-names>L</given-names></name><name><surname>Serra</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>D</given-names></name><name><surname>Domenzain</surname><given-names>C</given-names></name><name><surname>Docampo</surname><given-names>MJ</given-names></name><name><surname>Rabanal</surname><given-names>RM</given-names></name><name><surname>de Torres</surname><given-names>I</given-names></name><name><surname>Wight</surname><given-names>TN</given-names></name><name><surname>Fabra</surname><given-names>A</given-names></name><name><surname>Bassols</surname><given-names>A</given-names></name></person-group><article-title>V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis</article-title><source>Lab Investig</source><year>2006</year><volume>86</volume><issue>9</issue><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3700449</pub-id><?supplied-pmid 16847433?><pub-id pub-id-type="pmid">16847433</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciardelli</surname><given-names>C</given-names></name><name><surname>Brooks</surname><given-names>JH</given-names></name><name><surname>Suwiwat</surname><given-names>S</given-names></name><name><surname>Sakko</surname><given-names>AJ</given-names></name><name><surname>Mayne</surname><given-names>K</given-names></name><name><surname>Raymond</surname><given-names>WA</given-names></name><name><surname>Seshadri</surname><given-names>R</given-names></name><name><surname>LeBaron</surname><given-names>RG</given-names></name><name><surname>Horsfall</surname><given-names>DJ</given-names></name></person-group><article-title>Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><issue>4</issue><fpage>1054</fpage><lpage>1060</lpage><?supplied-pmid 11948113?><pub-id pub-id-type="pmid">11948113</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>WW</given-names></name><name><surname>Yang</surname><given-names>BB</given-names></name><name><surname>Shatseva</surname><given-names>TA</given-names></name><name><surname>Yang</surname><given-names>BL</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Shan</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>DY</given-names></name><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Yee</surname><given-names>AJ</given-names></name></person-group><article-title>Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><issue>11</issue><fpage>e13828</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0013828</pub-id><?supplied-pmid 21079779?><pub-id pub-id-type="pmid">21079779</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricciardelli</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>DL</given-names></name><name><surname>Ween</surname><given-names>MP</given-names></name><name><surname>Mayne</surname><given-names>K</given-names></name><name><surname>Suwiwat</surname><given-names>S</given-names></name><name><surname>Byers</surname><given-names>S</given-names></name><name><surname>Marshall</surname><given-names>VR</given-names></name><name><surname>Tilley</surname><given-names>WD</given-names></name><name><surname>Horsfall</surname><given-names>DJ</given-names></name></person-group><article-title>Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility</article-title><source>J Biol Chem</source><year>2007</year><volume>282</volume><issue>14</issue><fpage>10814</fpage><lpage>10825</lpage><pub-id pub-id-type="doi">10.1074/jbc.M606991200</pub-id><?supplied-pmid 17293599?><pub-id pub-id-type="pmid">17293599</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casey</surname><given-names>RC</given-names></name><name><surname>Oegema</surname><given-names>TJ</given-names></name><name><surname>Skubitz</surname><given-names>KM</given-names></name><name><surname>Pambuccian</surname><given-names>SE</given-names></name><name><surname>Grindle</surname><given-names>SM</given-names></name><name><surname>Skubitz</surname><given-names>AP</given-names></name></person-group><article-title>Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells</article-title><source>Clin Exp Metastasis</source><year>2003</year><volume>20</volume><issue>2</issue><fpage>143</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1023/A:1022670501667</pub-id><?supplied-pmid 12705635?><pub-id pub-id-type="pmid">12705635</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H</given-names></name><name><surname>Liyanarachchi</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>FA</given-names></name><name><surname>Davuluri</surname><given-names>R</given-names></name><name><surname>Lockman</surname><given-names>JC</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Pellegata</surname><given-names>NS</given-names></name></person-group><article-title>Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><issue>24</issue><fpage>15632</fpage><lpage>15637</lpage><pub-id pub-id-type="doi">10.1073/pnas.242597299</pub-id><?supplied-pmid 12438652?><pub-id pub-id-type="pmid">12438652</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Liu X, Xu D, Liu Z, Li Y, Zhang C, Gong Y, Jiang Y, Xing B. THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition. Clin Transl Oncol. 2020.</mixed-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioka</surname><given-names>T</given-names></name><name><surname>Eustace</surname><given-names>A</given-names></name><name><surname>West</surname><given-names>C</given-names></name></person-group><article-title>Lysyl oxidase: from basic science to future cancer treatment</article-title><source>Cell Struct Funct</source><year>2012</year><volume>37</volume><issue>1</issue><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1247/csf.11015</pub-id><?supplied-pmid 22453058?><pub-id pub-id-type="pmid">22453058</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csiszar</surname><given-names>K</given-names></name><name><surname>Fong</surname><given-names>SF</given-names></name><name><surname>Ujfalusi</surname><given-names>A</given-names></name><name><surname>Krawetz</surname><given-names>SA</given-names></name><name><surname>Salvati</surname><given-names>EP</given-names></name><name><surname>Mackenzie</surname><given-names>JW</given-names></name><name><surname>Boyd</surname><given-names>CD</given-names></name></person-group><article-title>Somatic mutations of the lysyl oxidase gene on chromosome 5q23.1 in colorectal tumors</article-title><source>Int J Cancer</source><year>2002</year><volume>97</volume><issue>5</issue><fpage>636</fpage><lpage>642</lpage><pub-id pub-id-type="doi">10.1002/ijc.10035</pub-id><?supplied-pmid 11807790?><pub-id pub-id-type="pmid">11807790</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Lei</surname><given-names>P</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><article-title>Human colorectal cancer progression correlates with LOX-induced ECM stiffening</article-title><source>Int J Biol Sci</source><year>2017</year><volume>13</volume><issue>11</issue><fpage>1450</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.7150/ijbs.21230</pub-id><?supplied-pmid 29209148?><pub-id pub-id-type="pmid">29209148</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>AM</given-names></name><name><surname>Cox</surname><given-names>TR</given-names></name><name><surname>Bird</surname><given-names>D</given-names></name><name><surname>Lang</surname><given-names>G</given-names></name><name><surname>Murray</surname><given-names>GI</given-names></name><name><surname>Sun</surname><given-names>XF</given-names></name><name><surname>Southall</surname><given-names>SM</given-names></name><name><surname>Wilson</surname><given-names>JR</given-names></name><name><surname>Erler</surname><given-names>JT</given-names></name></person-group><article-title>The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer</article-title><source>J Natl Cancer Inst</source><year>2011</year><volume>103</volume><issue>5</issue><fpage>407</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1093/jnci/djq569</pub-id><?supplied-pmid 21282564?><pub-id pub-id-type="pmid">21282564</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>H</given-names></name><name><surname>Stenling</surname><given-names>R</given-names></name><name><surname>Rubio</surname><given-names>C</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name></person-group><article-title>Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2</article-title><source>CARCINOGENESIS</source><year>2001</year><volume>22</volume><issue>6</issue><fpage>875</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1093/carcin/22.6.875</pub-id><?supplied-pmid 11375892?><pub-id pub-id-type="pmid">11375892</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>Q</given-names></name><name><surname>Ji</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>CDCA3 mediates p21-dependent proliferation by regulating E2F1 expression in colorectal cancer</article-title><source>Int J Oncol</source><year>2018</year><volume>53</volume><issue>5</issue><fpage>2021</fpage><lpage>2033</lpage><?supplied-pmid 30226575?><pub-id pub-id-type="pmid">30226575</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Yasui</surname><given-names>W</given-names></name><name><surname>Yokozaki</surname><given-names>H</given-names></name><name><surname>Naka</surname><given-names>K</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Tahara</surname><given-names>E</given-names></name></person-group><article-title>Expression of the E2F family in human gastrointestinal carcinomas</article-title><source>Int J Cancer</source><year>1999</year><volume>81</volume><issue>4</issue><fpage>535</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19990517)81:4&#x0003c;535::AID-IJC5&#x0003e;3.0.CO;2-4</pub-id><?supplied-pmid 10225440?><pub-id pub-id-type="pmid">10225440</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosil</surname><given-names>MA</given-names></name><name><surname>Navaridas</surname><given-names>R</given-names></name><name><surname>Mirantes</surname><given-names>C</given-names></name><name><surname>Tarragona</surname><given-names>J</given-names></name><name><surname>Eritja</surname><given-names>N</given-names></name><name><surname>Felip</surname><given-names>I</given-names></name><name><surname>Urdanibia</surname><given-names>I</given-names></name><name><surname>Megino</surname><given-names>C</given-names></name><name><surname>Domingo</surname><given-names>M</given-names></name><name><surname>Santacana</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tumor suppressive function of E2F-1 on PTEN-induced serrated colorectal carcinogenesis</article-title><source>J Pathol</source><year>2019</year><volume>247</volume><issue>1</issue><fpage>72</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1002/path.5168</pub-id><?supplied-pmid 30206933?><pub-id pub-id-type="pmid">30206933</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zacharatos</surname><given-names>P</given-names></name><name><surname>Kotsinas</surname><given-names>A</given-names></name><name><surname>Evangelou</surname><given-names>K</given-names></name><name><surname>Karakaidos</surname><given-names>P</given-names></name><name><surname>Vassiliou</surname><given-names>LV</given-names></name><name><surname>Rezaei</surname><given-names>N</given-names></name><name><surname>Kyroudi</surname><given-names>A</given-names></name><name><surname>Kittas</surname><given-names>C</given-names></name><name><surname>Patsouris</surname><given-names>E</given-names></name><name><surname>Papavassiliou</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas</article-title><source>J Pathol</source><year>2004</year><volume>203</volume><issue>3</issue><fpage>744</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1002/path.1582</pub-id><?supplied-pmid 15221933?><pub-id pub-id-type="pmid">15221933</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upp</surname><given-names>JJ</given-names></name><name><surname>Saydjari</surname><given-names>R</given-names></name><name><surname>Townsend</surname><given-names>CJ</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name><name><surname>Barranco</surname><given-names>SC</given-names></name><name><surname>Thompson</surname><given-names>JC</given-names></name></person-group><article-title>Polyamine levels and gastrin receptors in colon cancers</article-title><source>Ann Surg</source><year>1988</year><volume>207</volume><issue>6</issue><fpage>662</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1097/00000658-198806000-00004</pub-id><?supplied-pmid 3389934?><pub-id pub-id-type="pmid">3389934</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luk</surname><given-names>GD</given-names></name><name><surname>Goodwin</surname><given-names>G</given-names></name><name><surname>Marton</surname><given-names>LJ</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><article-title>Polyamines are necessary for the survival of human small-cell lung carcinoma in culture</article-title><source>Proc Natl Acad Sci U S A</source><year>1981</year><volume>78</volume><issue>4</issue><fpage>2355</fpage><lpage>2358</lpage><pub-id pub-id-type="doi">10.1073/pnas.78.4.2355</pub-id><?supplied-pmid 6264474?><pub-id pub-id-type="pmid">6264474</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manni</surname><given-names>A</given-names></name><name><surname>Grove</surname><given-names>R</given-names></name><name><surname>Kunselman</surname><given-names>S</given-names></name><name><surname>Aldaz</surname><given-names>CM</given-names></name></person-group><article-title>Involvement of the polyamine pathway in breast cancer progression</article-title><source>Cancer Lett</source><year>1995</year><volume>92</volume><issue>1</issue><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/0304-3835(95)03763-M</pub-id><?supplied-pmid 7757960?><pub-id pub-id-type="pmid">7757960</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Marengo</surname><given-names>SR</given-names></name><name><surname>MacLennan</surname><given-names>GT</given-names></name><name><surname>Greenberg</surname><given-names>NM</given-names></name><name><surname>Mukhtar</surname><given-names>H</given-names></name></person-group><article-title>Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><issue>18</issue><fpage>5125</fpage><lpage>5133</lpage><?supplied-pmid 11016639?><pub-id pub-id-type="pmid">11016639</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilmour</surname><given-names>SK</given-names></name></person-group><article-title>Polyamines and nonmelanoma skin cancer</article-title><source>Toxicol Appl Pharmacol</source><year>2007</year><volume>224</volume><issue>3</issue><fpage>249</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2006.11.023</pub-id><?supplied-pmid 17234230?><pub-id pub-id-type="pmid">17234230</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Weaver</surname><given-names>VM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>The extracellular matrix: a dynamic niche in cancer progression</article-title><source>J Cell Biol</source><year>2012</year><volume>196</volume><issue>4</issue><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1083/jcb.201102147</pub-id><?supplied-pmid 3283993?><pub-id pub-id-type="pmid">22351925</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotti</surname><given-names>S</given-names></name><name><surname>Piccoli</surname><given-names>M</given-names></name><name><surname>Rizzolio</surname><given-names>F</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Nitti</surname><given-names>D</given-names></name><name><surname>Agostini</surname><given-names>M</given-names></name></person-group><article-title>Extracellular matrix and colorectal Cancer: how surrounding microenvironment affects Cancer cell behavior?</article-title><source>J Cell Physiol</source><year>2017</year><volume>232</volume><issue>5</issue><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1002/jcp.25658</pub-id><?supplied-pmid 27775168?><pub-id pub-id-type="pmid">27775168</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>Role of angiogenesis in tumor growth and metastasis</article-title><source>Semin Oncol</source><year>2002</year><volume>29</volume><issue>6 Suppl 16</issue><fpage>15</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1053/sonc.2002.37263</pub-id><?supplied-pmid 12516034?><pub-id pub-id-type="pmid">12516034</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewczuk</surname><given-names>&#x00141;</given-names></name><name><surname>Pryczynicz</surname><given-names>A</given-names></name><name><surname>Guzi&#x00144;ska-Ustymowicz</surname><given-names>K</given-names></name></person-group><article-title>Cell adhesion molecules in endometrial cancer - a systematic review</article-title><source>Adv Med Sci</source><year>2019</year><volume>64</volume><issue>2</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.advms.2019.08.003</pub-id><?supplied-pmid 31539810?><pub-id pub-id-type="pmid">31539810</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafrenie</surname><given-names>RM</given-names></name><name><surname>Buckner</surname><given-names>CA</given-names></name><name><surname>Bewick</surname><given-names>MA</given-names></name></person-group><article-title>Cell adhesion and cancer: is there a potential for therapeutic intervention?</article-title><source>Expert Opin Ther Targets</source><year>2007</year><volume>11</volume><issue>6</issue><fpage>727</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1517/14728222.11.6.727</pub-id><?supplied-pmid 17504010?><pub-id pub-id-type="pmid">17504010</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>TL</given-names></name></person-group><article-title>The tumor microenvironment and its role in promoting tumor growth</article-title><source>ONCOGENE</source><year>2008</year><volume>27</volume><issue>45</issue><fpage>5904</fpage><lpage>5912</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.271</pub-id><?supplied-pmid 18836471?><pub-id pub-id-type="pmid">18836471</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridman</surname><given-names>WH</given-names></name><name><surname>Pag&#x000e8;s</surname><given-names>F</given-names></name><name><surname>Saut&#x000e8;s-Fridman</surname><given-names>C</given-names></name><name><surname>Galon</surname><given-names>J</given-names></name></person-group><article-title>The immune contexture in human tumours: impact on clinical outcome</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nrc3245</pub-id><?supplied-pmid 22419253?><pub-id pub-id-type="pmid">22419253</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>N</given-names></name><etal/></person-group><article-title>Tumor-infiltrating immune cells act as a marker for prognosis in colorectal Cancer</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>2368</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02368</pub-id><?supplied-pmid 31681276?><pub-id pub-id-type="pmid">31681276</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Lagorce-Pag&#x000e8;s</surname><given-names>C</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Camus</surname><given-names>M</given-names></name><name><surname>Berger</surname><given-names>A</given-names></name><name><surname>Wind</surname><given-names>P</given-names></name><etal/></person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><issue>5795</issue><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1126/science.1129139</pub-id><?supplied-pmid 17008531?><pub-id pub-id-type="pmid">17008531</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassannia</surname><given-names>H</given-names></name><name><surname>Ghasemi</surname><given-names>CM</given-names></name><name><surname>Atyabi</surname><given-names>F</given-names></name><name><surname>Nosouhian</surname><given-names>M</given-names></name><name><surname>Masjedi</surname><given-names>A</given-names></name><name><surname>Hojjat-Farsangi</surname><given-names>M</given-names></name><name><surname>Namdar</surname><given-names>A</given-names></name><name><surname>Azizi</surname><given-names>G</given-names></name><name><surname>Mohammadi</surname><given-names>H</given-names></name><name><surname>Ghalamfarsa</surname><given-names>G</given-names></name><etal/></person-group><article-title>Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine</article-title><source>Immunology</source><year>2020</year><volume>159</volume><issue>1</issue><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/imm.13126</pub-id><?supplied-pmid 31587253?><pub-id pub-id-type="pmid">31587253</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajihara</surname><given-names>M</given-names></name><name><surname>Takakura</surname><given-names>K</given-names></name><name><surname>Kanai</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>Z</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Takami</surname><given-names>S</given-names></name><name><surname>Shimodaira</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Ohkusa</surname><given-names>T</given-names></name><name><surname>Koido</surname><given-names>S</given-names></name></person-group><article-title>Dendritic cell-based cancer immunotherapy for colorectal cancer</article-title><source>World J Gastroenterol</source><year>2016</year><volume>22</volume><issue>17</issue><fpage>4275</fpage><lpage>4286</lpage><pub-id pub-id-type="doi">10.3748/wjg.v22.i17.4275</pub-id><?supplied-pmid 27158196?><pub-id pub-id-type="pmid">27158196</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuno</surname><given-names>R</given-names></name><name><surname>Kawada</surname><given-names>K</given-names></name><name><surname>Itatani</surname><given-names>Y</given-names></name><name><surname>Ogawa</surname><given-names>R</given-names></name><name><surname>Kiyasu</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>Y</given-names></name></person-group><article-title>The Role of Tumor-Associated Neutrophils in Colorectal Cancer</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><fpage>3</fpage></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>F</given-names></name></person-group><article-title>Prognostic significance of lymphocyte to monocyte ratio in colorectal cancer: a meta-analysis</article-title><source>Int J Surg</source><year>2018</year><volume>55</volume><fpage>128</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2018.05.030</pub-id><?supplied-pmid 29807167?><pub-id pub-id-type="pmid">29807167</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohga</surname><given-names>S</given-names></name><name><surname>Harvey</surname><given-names>SR</given-names></name><name><surname>Weaver</surname><given-names>RM</given-names></name><name><surname>Markus</surname><given-names>G</given-names></name></person-group><article-title>Localization of plasminogen activators in human colon cancer by immunoperoxidase staining</article-title><source>Cancer Res</source><year>1985</year><volume>45</volume><issue>4</issue><fpage>1787</fpage><lpage>1796</lpage><?supplied-pmid 3884145?><pub-id pub-id-type="pmid">3884145</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>SR</given-names></name><name><surname>Sait</surname><given-names>SN</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Bailey</surname><given-names>JL</given-names></name><name><surname>Penetrante</surname><given-names>RM</given-names></name><name><surname>Markus</surname><given-names>G</given-names></name></person-group><article-title>Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><issue>4</issue><fpage>1115</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)65214-5</pub-id><?supplied-pmid 10514394?><pub-id pub-id-type="pmid">10514394</pub-id></element-citation></ref></ref-list></back></article>